Abstract
To investigate molecular therapeutic targets in cancer metastasis, comparative proteomic analysis was performed using the isogenic colorectal cancer cell lines SW480 and SW620. Two potential metastasis related molecular targets were identified: fatty acid synthase and histone H4. Subsequently, metastatic SW620 cells were treated with six anti-cancerous components and suppressive effects were observed in target protein expression. Through comprehensive proteomic analysis, three of the tested compounds, oxaliplatin, ginsenoside 20(S)-Rg3 and curcumin, were determined to have a suppressive effect on fatty acid synthase and histone H4 expression [1]. The current article contains one table exhibiting a list of proteins differentially expressed in metastatic SW620 cell lines compared to the primary SW480 cell line (Supplementary Table 1). Additionally, six tables demonstrate proteome changes in SW620 resulting from the treatment of three chemotherapeutics and three natural components (Supplementary Tables 1–7). The anti-metastatic components revealed by the current proteomic analysis represent promising chemotherapeutic candidates for the treatment of colorectal adenocarcinoma.
Highlights
Cell culture and drug treatmentCells were cultured in a Dulbecco's modified eagle medium (DMEM, Gibco BRL Life Technologies, Grand Island, NY, USA) containing 10% fetal bovine serum (FBS), 50 units/mL of penicillin G and 50 mcg/mL of streptomycin which were purchased from Gibco BRL Life Technologies (Grand Island, NY, USA)
To investigate molecular therapeutic targets in cancer metastasis, comparative proteomic analysis was performed using the isogenic colorectal cancer cell lines SW480 and SW620
Cells were cultured in a Dulbecco's modified eagle medium (DMEM, Gibco BRL Life Technologies, Grand Island, NY, USA) containing 10% fetal bovine serum (FBS), 50 units/mL of penicillin G and 50 mcg/mL of streptomycin which were purchased from Gibco BRL Life Technologies (Grand Island, NY, USA)
Summary
Cells were cultured in a Dulbecco's modified eagle medium (DMEM, Gibco BRL Life Technologies, Grand Island, NY, USA) containing 10% fetal bovine serum (FBS), 50 units/mL of penicillin G and 50 mcg/mL of streptomycin which were purchased from Gibco BRL Life Technologies (Grand Island, NY, USA). Cells were maintained at 37 1C under humidified 95% air and 5% CO2 and grown to confluence in culture dishes (150 mm diameter) over 2 or 3 days and trypsinized and used for the experiments. Stock solutions of tested drugs were diluted to the desired concentration and were administered in the presence of DMEM with reduced serum (0.5% FBS). Namely oxaliplatin, sorafenib and 5-fluorouracil were treated at concentrations of 10 μM, 0.15 μM and 10 μM, and herbal dietary components, namely ginsenoside 20(S)-Rg3, curcumin and luteolin were treated at 10 μM, 20 μM and 50 μM, respectively
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
